Using the Igrov-1 model of PARPi-resistant ovarian cancer, we compared the PARPi sensitizing effect of methylstat with commercially available DNA histone demethylases, including JMJD-specific inhibitors GSK-J1 (JMJD3, KDM6A) [42–44] and PFI-90 (JMJD1B) [41] and GSK-LSD1 [47, 48], a non-JMJD demethylase LSD1 inhibitor. Here, KDM6A is linked to ovarian carcinoma.